Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
In this cohort study of patients with mCRPC, docetaxel rechallenge was associated with improved OS compared with cabazitaxel among patients who did not experience disease progression during prior docetaxel for mCRPC. These findings support docetaxel rechallenge as a treatment option for patients in this scenario.
Authors
- Chong-xian Pan (ORCID: https://orcid.org/0000-0002-8588-3994)
- June K. Corrigan (ORCID: https://orcid.org/0000-0002-7514-0177)
- Clark DuMontier (ORCID: https://orcid.org/0000-0003-2582-7816)
- Kenute Myrie
- John Bihn (ORCID: https://orcid.org/0000-0001-8029-8991)
- Karlynn E. Neu (ORCID: https://orcid.org/0000-0002-3481-813X)
- Kaitlin N. Swinnerton (ORCID: https://orcid.org/0000-0002-7429-9960)
- Matthew B. Rettig (ORCID: https://orcid.org/0000-0002-7394-3056)
- Elliot H. Akama‐Garren (ORCID: https://orcid.org/0000-0002-1690-2055)
- Pedro Coelho Barata (ORCID: https://orcid.org/0000-0002-8890-2951)
- Jennifer La (ORCID: https://orcid.org/0000-0003-2266-0221)
- Rhonda L. Bitting (ORCID: https://orcid.org/0000-0002-5253-0551)
- N. Fillmore
- Sergey Goryachev
- Matthew R. Cooperberg (ORCID: https://orcid.org/0000-0003-4339-6685)
- Channing Judith Paller (ORCID: https://orcid.org/0000-0003-3658-1858)
- Tanya Barauskas Dorff (ORCID: https://orcid.org/0000-0001-5990-298X)
- V. Nhan
- Jean M. Hansen
- Susan Halabi
- Rachel B. Ramoni
- Timothy R. Rebbeck
- Martin W. Schoen
- David M. Nanus
- Antonio Tito Fojo
- J. Michael Gaziano
- Richard L. Hauger
- John M. Culnan
- Heather H. Cheng
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- West Los Angeles College (US)
- San Francisco VA Medical Center (US)
- United States Department of Veterans Affairs (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Duke University (US)
- University of Washington (US)
- Cornell University (US)
- University of New England (US)
- University Hospitals of Cleveland (US)
- Johns Hopkins Medicine (US)
- VA Boston Healthcare System (US)
- University of California San Diego (US)
- Fred Hutch Cancer Center (US)
- VA San Diego Healthcare System (US)
- City of Hope (US)
- Prostate Cancer Research (GB)
- James J. Peters VA Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Durham VA Medical Center (US)
- VA St. Louis Health Care System (US)
- Department of Veterans Affairs (AU)
- Weill Cornell Medicine (US)
- Saint Louis University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.51231
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Prostate Cancer Foundation
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Bayer
- Novartis
- Sanofi
- FibroGen
- Exelixis
- Clovis Oncology
- Astellas Pharma
- Genentech
- University of California, Los Angeles
- Kite Pharma
- Foundation Medicine